The agreement grants DSM rights to c-LEcta’s proprietary alcohol dehydrogenases for enzyme screening programs and development of sustainable manufacturing routes for manufacturing of pharmaceutical active ingredients and intermediates.
DSM applies their InnoSyn route scouting to identify more cost efficient routes for the development and manufacture of drug intermediates and ingredients by combining biocatalytic solutions with advanced chemical and process technologies.
The new routes result in shorter cycle times due to fewer steps in the process with the same reliability and quality using more renewable starting materials.
DSM will also provide commercialization of sustainable enzyme-based manufacturing routes developed by their InnoSyn route scouting services for c-LEcta.
c-LEcta chief scientific officer Thomas Greiner-Stoffele said that they are pleased to have this cooperation with DSM which will give them useful benchmarks for our alcohol dehydrogenase collection.